DRMA
Dermata Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−1.63%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$6.00M
MomentumView details →
1D Return
−1.63%
YTD Return
−48.28%
RSI (14)
41.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$6.00M
RSI (14)
41.9
MomentumView details →
1D Return
−1.63%
YTD Return
−48.28%
SummaryUpdated Jun 1, 2026
Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in August 2021 and focuses on developing pharmaceutical treatments for medical and aesthetic dermatological conditions. As a clinical-stage biotech firm, Dermata has no commercial products yet and is currently advancing multiple drug candidates through various phases of clinical trials, with its lead compound targeting common skin conditions like acne, psoriasis, and rosacea.
Similar companies
Latest newsMore news →
Dermata Therapeutics announced the commercial launch of its Tome Foundational Treatment skincare product, now available for purchase on its website.10d agoDermata Therapeutics, Inc. signed a private placement agreement on August 18, 2026, to raise approximately $3.4 million in gross proceeds through the sale of common stock, pre-funded warrants, Series E warrants, and Series F warrants.19d agoDermata Therapeutics announced the launch date of its first commercial product, Tome Foundational Treatment, expected on August 25, 2026.24d ago